SCHEMBL6415809

SCHEMBL6415809

COC(=O)c1ccccc1NC(=O)CC(C)=O

nearest known ligand 0.84

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.84
ALDH1A1 P00352 6/20 0.70
HSD17B10 Q99714 5/20 0.70
L3MBTL1 Q9Y468 2/20 0.67
KDM4E B2RXH2 5/20 0.66
MAPK10 P53779 2/20 0.64
TSHR P16473 2/20 0.64
HTT P42858 1/20 0.61
GAA P10253 3/20 0.60
LMNA P02545 1/20 0.59
POLB P06746 1/20 0.59
ATM Q13315 1/20 0.59
MEN1 O00255 1/20 0.59
MAPK8 P45983 1/20 0.58
MAPK9 P45984 1/20 0.58
MAPT P10636 1/20 0.56
MAPK1 P28482 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10502377 0.91 KMT2A (1.00) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL12730395 0.87 KMT2A (0.78) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL26617636 0.87 KMT2A (0.84) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL11575355 0.86 KDM4E (0.72) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL9958465 0.85 KMT2A (0.81) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL31570129 0.84 KMT2A (0.59) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL1589861 0.83 KMT2A (0.78) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL5928699 0.83 KMT2A (0.78) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL4734803 0.83 KMT2A (0.78) KMT2AALDH1A1HSD17B10L3MBTL1KDM4E
SCHEMBL5947666 0.83 KDM4E (0.58) KMT2AALDH1A1KDM4EMAPK10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100475-A1 COMPOSITION FOR IMAGE RECORDING AND METHOD FOR PRODUCING SAME キヤノン株式会社 2025-05-15 WO disclosed
US-6861419-B2 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-03-01 US disclosed
EP-1324993-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2003-07-09 EP disclosed
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US disclosed
WO-2001079187-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES CYTOVIA, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP14, CASP4 KMT2A 4221/4885ALDH1A1 832/4885HSD17B10 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.